Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cellectis S.A. ADR
(NQ:
CLLS
)
2.380
+0.010 (+0.42%)
Streaming Delayed Price
Updated: 10:14 AM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cellectis S.A. ADR
< Previous
1
2
3
4
5
6
Next >
12 Health Care Stocks Moving In Thursday's Pre-Market Session
November 02, 2023
Via
Benzinga
Why Roku Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
November 02, 2023
Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 39.7% to $0.1143 in pre-market trading after falling 17% on Wednesday. LumiraDX recently announced the receipt of the Nasdaq delisting...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
November 02, 2023
Pre-market stock movers are a hot topic on Thursday and we're checking out all of the biggest ones worth watching this morning!
Via
InvestorPlace
Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023
November 01, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Dow Gains Over 100 Points; Fed Leaves Interest Rates Unchanged
November 01, 2023
U.S. stocks traded higher toward the end of trading, after the Federal Reserve announced its policy decision. The Dow traded up 0.40% to 33,185.41 while the NASDAQ rose 0.92% to 12,969.54. The S&P 500...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
12 Health Care Stocks Moving In Wednesday's Intraday Session
November 01, 2023
Via
Benzinga
Why Is Cancer Player Cellectis Stock Trading Over 100% Higher Today?
November 01, 2023
Cellectis SA (NASDAQ: CLLS) shares are trading higher after the company
Via
Benzinga
Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
November 01, 2023
Gainers
Via
Benzinga
Nasdaq Surges Over 100 Points Ahead Of Fed Decision; WeWork Shares Plunge
November 01, 2023
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Wednesday. The Dow traded up 0.55% to 33,233.33 while the NASDAQ rose 0.87% to 12,962.92. The...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
US Stocks Mixed; Private Sector Payrolls Increase Less Than Expected
November 01, 2023
U.S. stocks traded mixed this morning, ahead of interest rate decision from the Federal Reserve. Following the market opening Wednesday, the Dow traded down 0.05% to 33,036.63 while the NASDAQ rose...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Why Is WeWork (WE) Stock Down 38% Today?
November 01, 2023
WeWork stock is falling on Wednesday as investors in WE shares react to reports that the company is considering a bankruptcy filing.
Via
InvestorPlace
Topics
Bankruptcy
Exposures
Financial
Legal
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 01, 2023
Via
Benzinga
Why Is Paycom Software (PAYC) Stock Down 39% Today?
November 01, 2023
Paycom Software stock is falling hard on Wednesday as investors in PAYC go over the company's mixed earnings report for Q3 2023!
Via
InvestorPlace
Why Is Mainz Biomed (MYNZ) Stock Moving Today?
November 01, 2023
Mainz Biomed stock is on the move Wednesday as investors in MYNZ react to results from a colorectal cancer screening test campaign.
Via
InvestorPlace
Why Is Cellectis (CLLS) Stock Up 175% Today?
November 01, 2023
Cellectis stock is taking off on Wednesday as investors in CLLS react to a massive $245 million investment from AstraZeneca.
Via
InvestorPlace
Why Plus Therapeutics Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
November 01, 2023
Gainers
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
November 01, 2023
We're starting off Wednesday with a breakdown of the biggest pre-market stock movers investors will want to keep track of today!
Via
InvestorPlace
Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca
November 01, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
October 31, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress
October 24, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)
October 12, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
September 27, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Provides Full Report for Second Quarter 2023 Financial Results
August 07, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023
August 03, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023
July 27, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors
July 12, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023
June 28, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023
June 09, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event
June 05, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies
May 31, 2023
From
Cellectis Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.